Dibutyl Squaric Acid Topical Solution Recalled Due to CGMP Deviations
Edge Pharma, LLC is recalling 20 vials of Dibutyl Squaric Acid topical solution nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The drug was distributed in multiple dose vials containing 1%, 10 mL each.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving CGMP deviations in a drug product. The source text does not report any illnesses, injuries, or hospitalizations. The recall is classified as voluntary and precautionary in nature, warranting a Moderate severity level consistent with Class II recalls without reported adverse health events.
Plain-English summary
Edge Pharma, LLC is voluntarily recalling Dibutyl Squaric Acid, Topical Solution (PF) Multiple Dose Vial, 1%, 10 mL per vial (NDC 05446-1156-03) nationwide. A total of 20 vials are affected by this recall.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified by the manufacturer. The affected product has lot codes 08-2021-03@8 with an expiration date of 12-31-2021 and 09-2021-07@10 with an expiration date of 02-04-2022.
The U.S. Food and Drug Administration classified this as a Class II recall. Consumers in possession of affected vials should contact their healthcare provider or pharmacist for guidance. The recall was initiated on December 6, 2021, and has been terminated as of June 7, 2023.
The recalled product
- Product
- Dibutyl Squaric Acid, Topical Solution (PF) Multiple Dose Vial, 1%, 10 mL per vial, Edge Parma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1156-03
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Topical Solution
- Hazard
- cgmp-deviation
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 08-2021-03@8 12-31-2021 & 09-2021-07@10 02-04-2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27